Appendix – vCJD countries of risk – Europe

This list is subject to change due to updates by the Food and Drug Administration. It is possible that FDA has issued a more current list of countries. Users are responsible for maintaining a current list of the countries. This list is of European countries to be used for deferral of donors based on geographic risk of Bovine Spongiform Encephalopathy (BSE).⁴

Countries in Europe:

Albania	Macedonia
Austria	Netherlands
Belgium	Norway
Bosnia-Herzegovina	Poland
Bulgaria	Portugal
Croatia	Romania
Czech Republic	Slovak Republic
Denmark	Slovenia
Finland	Spain
France	Sweden
Germany	Switzerland
Greece	United Kingdom
Hungary	Yugoslavia*
Ireland	Montenegro*, **
Italy	Serbia*, **
Liechtenstein	

Luxembourg

*U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) dated August 2007. <u>https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryin</u> <u>formation/guidances/tissue/ucm091345.pdf</u> * NOTE: Yugoslavia became the federated union of Serbia and Montenegro in 2003 (which further separated into its component parts in 2006). *Reference:* Yugoslavia, Former Federated Nation [1929-2003], Encyclopaedia Britanncia. Available at: <u>https://www.britannica.com/place/Yugoslavia-former-federated-nation-1929-2003</u>

** NOTE: Montenegro and Serbia do not appear in the August 2007 FDA guidance document, "Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)". Montenegro and Serbia have been added to this list, "Appendix – vCJD countries of risk – Europe" due to Yugoslavia no longer existing, and Montenegro and Serbia existing in Yugoslavia's former geographic region.

*U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) dated August 2007. <u>https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryin</u> <u>formation/guidances/tissue/ucm091345.pdf</u>